Reopening a good bet with high costsNearly two weeks into Thailand's official reopening during the Covid-19 pandemic, it is time to evaluate the country's vaccine management plan, economic costs and prospects of recovery. While the reopening is worth the attendant risks, Thailand is paying a disproportionately high price for earlier mistakes and the government's mismanagement. The local production of the AstraZeneca vaccine was delayed and short of target. It should have led to the transfer and demotion of elected officials and public health bureaucrats involved but so far there has been no accountability. This means the reopening is a big bet on public health.
